Neuralstem (CUR) 3.01 $CUR
Morning Briefing on Biotech Stocks -- Research on Dynavax Technologies, Synergy Pharma, Infinity Pharma, and Neuralstem
PR Newswire - Wed Jul 02, 6:00AM CDT
On Tuesday, July 01, 2014, the NASDAQ Composite ended at 4,458.65, up 1.14%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,956.07, and the S&P 500 closed at 1,973.32, up 0.67%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.38, up 1.26%, with the index also advancing 4.64% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Neuralstem Inc. (NYSE MKT: CUR). Free technical research on DVAX, SGYP, INFI and CUR can be downloaded upon signing up at:
Neuralstem reports membership in Russell 3000 Index
M2 - Tue Jul 01, 3:13AM CDT
Neural stem cells company Neuralstem (NYSE MKT:CUR) announced on Monday the addition of its shares to the broad-market Russell 3000 Index.
Neuralstem Added To Russell 3000 Index
PR Newswire - Mon Jun 30, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index.
Neuralstem Up 8.1%, Shares Break Through Resistance (CUR)
Comtex SmarTrend(R) - Wed Jun 25, 11:39AM CDT
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 8.1% to $4.67 on 1.6x average daily volume. Neuralstem has traded 1.5 million shares thus far today, vs. average volume of 907,000 shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.1%) and outperformed the S&P 500 (8.1% to the S&P's 0.2%) during today's trading.
Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder
PR Newswire - Wed Jun 25, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 2014. NSI-189 is Neuralstem's lead proprietary neurogenic compound. At yesterday's CINP meeting, a poster presentation on quantitative EEG (qEEG) measurements, an electrophysical biomarker of depression, taken during the course of study showed that patients in the active treatment arm of the study:
Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress
PR Newswire - Thu Jun 19, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that select data from the NSI-189 Phase Ib trial in patients with major depressive disorder (MDD) will be presented at the International College of Neuropyschopharmacology (CINP) 2014 World Congress, in Vancouver, Canada. A poster entitled, "Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blinded, placebo controlled, multiple ascending dose study," will be presented in the session "Biomarkers (incl. pharmacogenomics and brain imaging) for diagnosis and treatment response" on June 24th from 5:15 to 6:45 p.m. PDT.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting
PR Newswire - Wed Jun 18, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that final data from the Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD) was presented yesterday at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound, shown to promote neurogenesis in vitro. In animal studies, NSI-189 resulted in a 20% increase in hippocampal volume. In a presentation called, "A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, A Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)," Marlene Freeman, MD, Medical Director, Clinical Trials Network and Institute, Massachusetts General Hospital, and Associate Professor of Psychiatry, Harvard Medical School, reported clinically meaningful reduction in cognitive and depressive symptoms across all measures in depressed patients on active therapy against the control group. These positive gains in both cognitive function and diminishment of depression symptoms continued for the duration of the trial, eight weeks after the 28-day treatment had stopped. The abstract can be found on page 73 of the abstract book http://ascpmeeting.org/wp-content/uploads/201...Online.pdf
Ischemic Stroke - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2fmkd/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - BioTime, Inc. - Athersys, Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - FibroGen, Inc. - Panacea Pharmaceuticals, Inc. - Acorda Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Celgene Corporation - Neuralstem, Inc. - Mesoblast Limited - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - Huons Co., Ltd. - NeuroVive Pharmaceutical AB - Digna Biotech, S.L. - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Virogenomics, Inc. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. - Tarix Pharmaceuticals LTD. - International Biotechnology Center Generium - MediaPharma s.r.l. For more information visit http://www.researchandmarkets.com/research/c2...mic_stroke
Neuralstem, Inc. - "The FDA is Not the Enemy"
ACCESSWIRE - Mon Jun 09, 8:26AM CDT
New York, NY / June 9, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) published a new blog post on the Company's website which was republished on TheChairmansBlog.com, written by the Company's President and CEO, Richard Garr. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma
PR Newswire - Thu May 29, 5:50AM CDT
The US markets saw a negative sentiment on Wednesday, May 28, 2014, with the NASDAQ Composite closing at 4,225.08, down 0.28%, the Dow Jones Industrial Average ending the session at 16,633.18, down 0.25% and the S&P 500 finishing 0.11% lower at 1,909.78. During the trading session, five out of ten sectors finished on a lower note. Investor-Edge has initiated coverage on the following equities: GTx Inc. (NASDAQ: GTXI), Iridium Communications Inc. (NASDAQ: IRDM), Neuralstem Inc. (NYSE MKT: CUR) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on GTXI, IRDM, CUR and IDRA can be downloaded upon signing up at:
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Neuralstem, Inc. - "Most men would rather deny a hard truth than face it"
ACCESSWIRE - Wed May 28, 10:36AM CDT
New York, NY / May 28, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) today published a new blog post on the Company's website which was republished on TheChairmansBlog.com (http://www.thechairmansblog.com/neuralstem/richard-garr/men-rather-deny-hard-truth-face/), written by the Company's President and CEO, Richard Garr. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting
PR Newswire - Fri May 23, 8:28AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida, on June 17th at 4:15 EDT. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound. In pre-clinical studies, NSI-189 was shown to promote the formation of new neurons (neurogenesis) in animals and in human hippocampus-derived neural stem cells. In "A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, A Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)," found on page 73 of the abstract book http://ascpmeeting.org/wp-content/uploads/201...Online.pdf, study author, Marlene Freeman, MD, Medical Director, Clinical Trials Network and Institute, Massachusetts General Hospital, and Associate Professor of Psychiatry, Harvard Medical School, will discuss trial results, including that depressed patients on two different doses showed clinically meaningful reductions in depressive and cognitive symptoms across all measures against placebo. Furthermore, these improvements appeared to persist throughout the follow up period. Based on the results, the investigators, including lead study author, Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital, concluded that a neurogenesis-based platform could identify promising new treatments for major depressive disorder.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Why Neuralstem Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem a clinical-stage...
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
PR Newswire - Fri Mar 28, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the application of the cells for transplantation therapy in ischemic stroke. The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients
Equities Recording New Highs: Generac Holding, Sempra Energy, Neuralstem, and Great Plains Energy
PR Newswire - Tue Mar 18, 8:41AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Generac Holdings Inc. (NYSE:GNRC), Sempra Energy (NYSE:SRE), Neuralstem Inc. (NYSE MKT: CUR), and Great Plains Energy Inc. (NYSE:GXP). Free research on these four companies can be accessed at:
Why Neuralstem Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 12:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem , a clinical-stage...
Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
PR Newswire - Mon Mar 17, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full. In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes," results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial. These six patients were the first to receive cervical stem cell transplants. Three of them were also the first to be transplanted along the length of their spines, in both the lumbar and the cervical regions. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits. This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.
Morning Briefing on Biotech Stocks -- Research on Dynavax Technologies, Synergy Pharma, Infinity Pharma, and Neuralstem
PR Newswire - Wed Jul 02, 6:00AM CDT
On Tuesday, July 01, 2014, the NASDAQ Composite ended at 4,458.65, up 1.14%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,956.07, and the S&P 500 closed at 1,973.32, up 0.67%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.38, up 1.26%, with the index also advancing 4.64% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Neuralstem Inc. (NYSE MKT: CUR). Free technical research on DVAX, SGYP, INFI and CUR can be downloaded upon signing up at:
Neuralstem reports membership in Russell 3000 Index
M2 - Tue Jul 01, 3:13AM CDT
Neural stem cells company Neuralstem (NYSE MKT:CUR) announced on Monday the addition of its shares to the broad-market Russell 3000 Index.
Neuralstem Added To Russell 3000 Index
PR Newswire - Mon Jun 30, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index.
Neuralstem Up 8.1%, Shares Break Through Resistance (CUR)
Comtex SmarTrend(R) - Wed Jun 25, 11:39AM CDT
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 8.1% to $4.67 on 1.6x average daily volume. Neuralstem has traded 1.5 million shares thus far today, vs. average volume of 907,000 shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.1%) and outperformed the S&P 500 (8.1% to the S&P's 0.2%) during today's trading.
Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder
PR Newswire - Wed Jun 25, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 2014. NSI-189 is Neuralstem's lead proprietary neurogenic compound. At yesterday's CINP meeting, a poster presentation on quantitative EEG (qEEG) measurements, an electrophysical biomarker of depression, taken during the course of study showed that patients in the active treatment arm of the study:
Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress
PR Newswire - Thu Jun 19, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that select data from the NSI-189 Phase Ib trial in patients with major depressive disorder (MDD) will be presented at the International College of Neuropyschopharmacology (CINP) 2014 World Congress, in Vancouver, Canada. A poster entitled, "Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blinded, placebo controlled, multiple ascending dose study," will be presented in the session "Biomarkers (incl. pharmacogenomics and brain imaging) for diagnosis and treatment response" on June 24th from 5:15 to 6:45 p.m. PDT.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting
PR Newswire - Wed Jun 18, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that final data from the Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD) was presented yesterday at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound, shown to promote neurogenesis in vitro. In animal studies, NSI-189 resulted in a 20% increase in hippocampal volume. In a presentation called, "A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, A Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)," Marlene Freeman, MD, Medical Director, Clinical Trials Network and Institute, Massachusetts General Hospital, and Associate Professor of Psychiatry, Harvard Medical School, reported clinically meaningful reduction in cognitive and depressive symptoms across all measures in depressed patients on active therapy against the control group. These positive gains in both cognitive function and diminishment of depression symptoms continued for the duration of the trial, eight weeks after the 28-day treatment had stopped. The abstract can be found on page 73 of the abstract book http://ascpmeeting.org/wp-content/uploads/201...Online.pdf
Ischemic Stroke - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2fmkd/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - BioTime, Inc. - Athersys, Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - FibroGen, Inc. - Panacea Pharmaceuticals, Inc. - Acorda Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Celgene Corporation - Neuralstem, Inc. - Mesoblast Limited - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - Huons Co., Ltd. - NeuroVive Pharmaceutical AB - Digna Biotech, S.L. - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Virogenomics, Inc. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. - Tarix Pharmaceuticals LTD. - International Biotechnology Center Generium - MediaPharma s.r.l. For more information visit http://www.researchandmarkets.com/research/c2...mic_stroke
Neuralstem, Inc. - "The FDA is Not the Enemy"
ACCESSWIRE - Mon Jun 09, 8:26AM CDT
New York, NY / June 9, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) published a new blog post on the Company's website which was republished on TheChairmansBlog.com, written by the Company's President and CEO, Richard Garr. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma
PR Newswire - Thu May 29, 5:50AM CDT
The US markets saw a negative sentiment on Wednesday, May 28, 2014, with the NASDAQ Composite closing at 4,225.08, down 0.28%, the Dow Jones Industrial Average ending the session at 16,633.18, down 0.25% and the S&P 500 finishing 0.11% lower at 1,909.78. During the trading session, five out of ten sectors finished on a lower note. Investor-Edge has initiated coverage on the following equities: GTx Inc. (NASDAQ: GTXI), Iridium Communications Inc. (NASDAQ: IRDM), Neuralstem Inc. (NYSE MKT: CUR) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on GTXI, IRDM, CUR and IDRA can be downloaded upon signing up at:
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Neuralstem, Inc. - "Most men would rather deny a hard truth than face it"
ACCESSWIRE - Wed May 28, 10:36AM CDT
New York, NY / May 28, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) today published a new blog post on the Company's website which was republished on TheChairmansBlog.com (http://www.thechairmansblog.com/neuralstem/richard-garr/men-rather-deny-hard-truth-face/), written by the Company's President and CEO, Richard Garr. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting
PR Newswire - Fri May 23, 8:28AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida, on June 17th at 4:15 EDT. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound. In pre-clinical studies, NSI-189 was shown to promote the formation of new neurons (neurogenesis) in animals and in human hippocampus-derived neural stem cells. In "A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, A Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)," found on page 73 of the abstract book http://ascpmeeting.org/wp-content/uploads/201...Online.pdf, study author, Marlene Freeman, MD, Medical Director, Clinical Trials Network and Institute, Massachusetts General Hospital, and Associate Professor of Psychiatry, Harvard Medical School, will discuss trial results, including that depressed patients on two different doses showed clinically meaningful reductions in depressive and cognitive symptoms across all measures against placebo. Furthermore, these improvements appeared to persist throughout the follow up period. Based on the results, the investigators, including lead study author, Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital, concluded that a neurogenesis-based platform could identify promising new treatments for major depressive disorder.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Why Neuralstem Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem a clinical-stage...
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
PR Newswire - Fri Mar 28, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the application of the cells for transplantation therapy in ischemic stroke. The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients
Equities Recording New Highs: Generac Holding, Sempra Energy, Neuralstem, and Great Plains Energy
PR Newswire - Tue Mar 18, 8:41AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Generac Holdings Inc. (NYSE:GNRC), Sempra Energy (NYSE:SRE), Neuralstem Inc. (NYSE MKT: CUR), and Great Plains Energy Inc. (NYSE:GXP). Free research on these four companies can be accessed at:
Why Neuralstem Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 12:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem , a clinical-stage...
Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
PR Newswire - Mon Mar 17, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full. In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes," results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial. These six patients were the first to receive cervical stem cell transplants. Three of them were also the first to be transplanted along the length of their spines, in both the lumbar and the cervical regions. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits. This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.
